Fin Cascade

Prices as of 9 Oct 2026 close · Not investment advice

Protean eGov Technologies Limited

NSE: PROTEANIT Enabled Services

Share price

₹640.65

+0.31% close of 9 Oct 2026

Market cap ₹2,627 CrP/E 30.5

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

61

out of 100 · worked out 9 Oct 2026

How the business score works

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹2,627 Cr

P/E ratio

30.5

P/B ratio

2.4

ROCE

12.7%

ROE

10.0%

Dividend yield

1.6%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹875.4052-week low ₹446.40

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 21.4% over the past year, and 6.3% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales slipped from 16.3% to 10.7% over the last three years.

Whether it grew faster than its sector

It grew 6.3% a year against a sector median of 14.5% — 8.2 percentage points slower.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

Its earnings are falling, so growth cannot justify the price.

Profit growthPrice per ₹1 profitPer 1% growth
Protean eGov Technologies Limited — this one-1%/yr30.5×—
L&T Technology Services Limited6%/yr25.5×₹4.3
Inventurus Knowledge Solutions Limited30%/yr38.2×₹1.3
Tata Technologies Limited-1%/yr44.5×—
Netweb Technologies India Limited64%/yr99.9×₹1.6
SAGILITY LIMITED86%/yr20.0×₹0.23

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (IT Enabled Services), it ranks 30 of 58 on returns, 38 of 54 on growth, 26 of 58 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 12.7% on capital, ahead of 48% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹332 crore of cash from the business, spent ₹161 crore on plant and equipment, and returned ₹145 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 8 years, about 71 arrived as cash. Its cash comes back faster than it used to: it went from being waiting 41 days for its cash to paid 8 days before it paid its own suppliers.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 10 checks clear · 80%

How the profit check works

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Profit fell 75% on ₹18 crore of upfront project spending, with revenue up 19%

Announced 4 Aug 2026 · Consolidated · Unaudited

Revenue

₹251 Cr

Revenue vs last year

+19.0%

Revenue vs last quarter

-18.4%

Net profit

₹6 Cr

Profit vs last year

-75.4%

Profit vs last quarter

-80.7%

Net margin

2.3%

EPS

₹1.44

Earnings call transcript · 4 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹2,627 Cr
Prev close
₹640.65
52w High
₹885
52w Low
₹444
Enterprise value
₹2,388 Cr
Beta
1.3
Price CAGR 1y
-23.0%
Price CAGR 3y
—
Price CAGR 5y
—
Price CAGR 10y
—

Ratios

Return on assets
6.9%
PEG ratio
-30.3
P/E ratio
30.5
P/B ratio
2.4
EV / EBITDA
21.4
Industry P/E
26.9
ROCE
12.7%
ROCE 5y average
15.0%
ROE
10.0%
Debt / Equity
0.1
Interest coverage
19.6
Dividend yield
1.6%
ROE 3y average
10.0%
ROE last year
10.0%

Annual P&L

Annual revenue
₹998 Cr
Annual profit
₹101 Cr
Operating margin
12.0%
Net profit margin
10.1%
EBITDA margin
11.6%
Sales growth 3y
10.4%
Sales growth 5y
10.6%
Profit growth 3y
-1.0%
Profit growth 5y
3.0%
EPS
₹24.8
Sales growth TTM
21.0%
Profit growth TTM
-10.0%
Dividend payout
40.0%

Quarter P&L

Sales latest quarter
₹251 Cr
Profit latest quarter
₹6 Cr
YoY quarterly sales growth
19.0%
YoY quarterly profit growth
-75.4%
OPM latest quarter
5.0%

Balance Sheet

Book Value
₹263
Face Value
₹10.0
Total debt
₹87 Cr
Total cash
₹187 Cr
Borrowings
₹87 Cr
Reserves / Equity
25.3

Cash Flow

Operating cash flow
₹78 Cr
Free cash flow
₹12 Cr
FCF yield
0.2%
Net cash flow
₹10 Cr

Shareholding

Promoter holding
—
FII holding
6.0%
DII holding
21.2%
Public holding
72.8%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
L&T Technology3,217.4525.434,1331.79357.117.42,940.111.526.7
Inventurus Knowl1,767.4539.730,3410.00193.727.9893.620.731.5
Tata Technolog.703.7043.928,5741.19180.86.21,664.633.820.9
Netweb Technol.4,708.85107.427,9930.0685.3179.9819.7172.137.5
Sagility43.4719.720,3500.35216.853.01,963.527.613.4
Affle 3i1,414.0041.719,9250.00128.421.7747.220.416.8
ESDS Software1,424.55135.316,6970.0029.314.0133.77.330.2
Protean eGov641.8530.42,6171.565.9-75.4251.019.012.7
Median226.4026.98580.008.820.8110.920.716.4

Competes with: Affle 3i Limited, Amagi Media Labs Limited, Black Box Limited, Cyient Limited, ESDS Software Solution Limited, Inventurus Knowledge Solutions Limited, L&T Technology Services Limited, Netweb Technologies India Limited, SAGILITY LIMITED, Srit India Limited, Tata Technologies Limited

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales220236204222197220202222211251229308251
Expenses186199207200181188187204194221197270239
Material Cost000000
Change in Inventories000000
Purchases of Stock-in-Trade000000
Employee Cost505860565869
Other Expenses154136161141211169
Operating Profit3436-3.0822153216181629323812
OPM %1515-1.519.877.69147.808.057.781214124.95
Other Income13132913191419172915101515
Exceptional items (within Other Income)000-3.95-0.750
Interest0.220.410.520.520.500.490.261.091.521.511.572.082.65
Depreciation4.915.486.19116.777.145.818.101110111418
Profit before tax4243192427382925323229367.64
Tax %23242118222520192626241723
Net Profit3233151921282320242423305.86
EPS in Rs7.968.103.774.775.216.925.665.035.885.885.547.481.44
Diluted EPS in Rs55.855.855.527.461.43

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales7557166036917418828419981,038
Expenses578568518567623792760882926
Material Cost00
Change in Inventories00
Purchases of Stock-in-Trade00
Employee Cost189233
Other Expenses572650
Operating Profit177148851241188980116112
OPM %232114181610101211
Other Income333849794268686855
Exceptional items (within Other Income)0-4.70
Interest2210122.346.688
Depreciation282717171827284753
Profit before tax180157116186140128118130106
Tax %3223202224242223
Net Profit12412192144107979210183
EPS in Rs313023362624232520
Diluted EPS in Rs2325
Dividend Payout %00012638424440

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
—
5 years
11%
3 years
10%
TTM
21%

Compounded profit growth

10 years
—
5 years
3%
3 years
-1%
TTM
-10%

Stock price CAGR

10 years
—
5 years
—
3 years
—
1 year
-23%

Return on equity

10 years
—
5 years
12%
3 years
10%
Last year
10%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital4040404040404141
Reserves6267146287488178869581,037
Borrowings20146128216987
Other Liabilities184172189188239238239309
Minority Interest00
Total Liabilities8709408639881,1041,1851,3071,474
Fixed Assets1576457656386153167
CWIP551411131119
Investments373406285364529550661638
Other Assets335465519555501536482650
Total Assets8709408639881,1041,1851,3071,474

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity1365410011-85819378
Cash from Investing Activity-104-13116-1391219-159-14
Cash from Financing Activity-39-39-183-1-1-47-42-54
Net Cash Flow-7232-129229-810
Free Cash Flow10942914-162614511

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days88107120106103786375
Cash Conversion Cycle88107120106103786375
Working Capital Days2599100411820-24-8
ROCE %22151917141213

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
FIIs119.748.616.719.90118.787.777.548.626.01
DIIs5141302930282522212121
Public3849616460616671717073
No. of Shareholders95,6781,46,3131,57,9751,60,6381,94,6232,09,5382,42,1852,37,7192,28,2202,17,4972,16,038

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -26.3% (₹869.15 → ₹640.65)Brick size ₹33.94 (fixed)Bricks 25
₹600₹800₹641Dec '25Feb '26Apr '26Aug '26
Price moved up one brickPrice moved down one brickLast close ₹640.65 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-239inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

1,18,95,113inr

2026-03-31

News

News and filings about Protean eGov Technologies Limited. Open one to see why it matters.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Sells to

  • Bima Sugam India Federation · end-to-end development, implementation and maintenance of the Bima Sugam digital insurance…
  • Government of Ethiopia · digital public infrastructure / national ID and AI-powered agriculture platform (export or…
  • Government of India · Central AgriStack digital public infrastructure and data-exchange framework
  • Income Tax Department, Government of India · Tax Information Network management; PAN/TAN issuance & reissuance; online PAN verification…
  • Pension Fund Regulatory and Development Authority (PFRDA) · Central Recordkeeping Agency for NPS and APY (~97% NPS, 100% APY market share)

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Information Technology
Industry
IT Enabled Services
Classification
Information Technology › IT Enabled Services
ISIN
INE004A01022

News impact

Big market events that reach Protean eGov Technologies Limited, and how the effect spreads.

Who it hits first

  • Primary beneficiaries are UNLISTED GST-tech vendors (GSTN, Cleartax, Zoho, Tally) — no tradeable signal.

Who may gain

  • Tax-tech/compliance SaaS and e-governance IT vendors winning incremental government digitisation mandates
  • Refund-heavy SMEs/exporters via faster GST refund cycles (working-capital easing)

Along the supply chain

Downstream

Faster GST refunds and cleaner AI-based invoice/e-way-bill matching ease working-capital cycles and reduce shipment/credit disputes for refund-heavy SMEs and exporters downstream (textiles, pharma, auto-ancillaries, logistics) — a small operational tailwind.

Upstream

GST-tech delivery relies on cloud/data-centre capacity and systems integrators; an AI-compliance push modestly lifts upstream demand for cloud infrastructure and SI capacity serving GSTN and tax-tech vendors.

Where demand moves

Business

Incremental government digitisation demand flows to e-governance/tax-tech vendors — listed PROTEAN, ZAGGLE, NEWGEN, with most capture by unlisted incumbents (GSTN, Cleartax, Zoho, Tally); automation may partly substitute manual paid-compliance work, making the net demand for paid-compliance SaaS two-sided.

Capital

Theme is too diffuse and medium-term to drive meaningful capital rotation; any thematic interest would tilt toward listed tax-tech/e-gov pure-plays, but low magnitude keeps institutional flows muted.

How it spreads across sectors

BFSI

Faster GST refunds and AI-verified invoice data modestly ease SME working-capital cycles and can improve SME-lending underwriting visibility.

Information Technology

Incremental, medium-term govt digitisation demand for compliance automation; low magnitude, spread across listed and unlisted vendors.

codex additions

  • Exporters/Textiles: faster refunds free blocked input-tax-credit, easing working capital (KPRMILL, TRIDENT, WELSPUNLIV)
  • Pharma exporters: quicker refunds on inverted-duty/exports aid cash conversion (SUNPHARMA, AUROPHARMA, DIVISLAB)
  • Auto ancillaries: simpler input-credit reconciliation across multi-state vendor chains (MOTHERSON, BOSCHLTD, UNOMINDA)
  • Logistics: cleaner e-way-bill/invoice matching reduces shipment holds (DELHIVERY, TCI, VRLLOG)
  • SME-focused NBFCs/supply-chain finance: GST-data-driven underwriting and invoice-backed lending (CREDITACC, SBFC, MASFIN)
  • Staffing/BPO: transition work around GST process redesign near-term, automation headwind long-term (TEAMLEASE, SIS, QUESS)

When it plays out

Immediate

Minimal price reaction — anniversary/roadmap commentary, not a discrete policy action; no effective date or rate change.

Medium term

If AI-led compliance and faster refunds are funded, structural tailwind for listed e-gov/tax-tech vendors and a working-capital easing for refund-heavy SMEs/exporters; automation may compress manual paid-compliance demand.

Short term

Watch GST Council / GSTN announcements for concrete AI-compliance tenders or refund-cycle SLAs that would convert the theme into orders.

Other sectors it reaches

  • {"causal_chain":"Faster GST refund processing lowers blocked input-tax-credit balances for exporters, improving working-capital turnover in refund-heavy textiles/apparel.","direction":"positive","example_tickers":["KPRMILL","TRIDENT","WELSPUNLIV"],"magnitude":"medium","notes":"Depends on actual refund-cycle compression and export order environment.","sector":"Exporters / Textiles \u0026 Apparel","time_horizon":"1_to_6_months"}
  • {"causal_chain":"AI-led compliance and faster refunds reduce GST credit mismatches and speed cash recovery on exports/inverted-duty structures.","direction":"positive","example_tickers":["SUNPHARMA","AUROPHARMA","DIVISLAB"],"magnitude":"small","notes":"Large balance sheets dilute impact.","sector":"Pharmaceuticals \u0026 Healthcare Exporters","time_horizon":"1_to_6_months"}
  • {"causal_chain":"Simpler GST processes lower compliance friction across multi-state supplier networks, easing input-credit reconciliation for component makers.","direction":"positive","example_tickers":["MOTHERSON","BOSCHLTD","UNOMINDA"],"magnitude":"small","notes":"More relevant for supplier-heavy businesses than OEMs.","sector":"Auto Ancillaries","time_horizon":"1_to_6_months"}
  • {"causal_chain":"GST simplification plus AI compliance yields cleaner e-way-bill/invoice matching, fewer disputes and shipment holds.","direction":"positive","example_tickers":["DELHIVERY","TCI","VRLLOG"],"magnitude":"small","notes":"Incremental efficiency ripple on an already GST-benefited sector.","sector":"Logistics \u0026 Express Distribution","time_horizon":"1_to_4_weeks"}
  • {"causal_chain":"Faster refunds and simplified input-credit reconciliation lower working-capital drag in high-inventory multi-state distribution.","direction":"positive","example_tickers":["DIXON","VOLTAS","BLUESTARCO"],"magnitude":"small","notes":"Strongest where input-credit accumulation is material.","sector":"Consumer Durables \u0026 Electronics Manufacturing","time_horizon":"1_to_6_months"}
  • {"causal_chain":"Simpler GST and quicker refunds reduce compliance burden for project-based manufacturers with large vendor bases.","direction":"positive","example_tickers":["ABB","SIEMENS","BHEL"],"magnitude":"small","notes":"Operational rather than demand-transforming.","sector":"Capital Goods / Industrial Manufacturing","time_horizon":"1_to_6_months"}
  • {"causal_chain":"Faster GST refunds and AI-driven invoice compliance improve verified SME cash-flow data, aiding underwriting and repayment visibility.","direction":"positive","example_tickers":["CREDITACC","SBFC","MASFIN"],"magnitude":"medium","notes":"GST-data-driven SME credit and invoice-backed lending.","sector":"SME-Focused NBFCs \u0026 Supply-Chain Finance","time_horizon":"1_to_6_months"}
  • {"causal_chain":"GST simplification raises formalization among small manufacturers, lifting documented invoicing and compliant packaging demand.","direction":"positive","example_tickers":["TCPLPACK","UFLEX","JKPAPER"],"magnitude":"small","notes":"Second-order formalization effect; gradual.","sector":"Paper, Packaging \u0026 Printing","time_horizon":"1_to_6_months"}
  • {"causal_chain":"AI-led compliance rollout still needs process redesign, reconciliations and audit support near-term, but automation reduces manual compliance headcount over time.","direction":"mixed","example_tickers":["TEAMLEASE","SIS","QUESS"],"magnitude":"small","notes":"Near-term transition work vs long-term automation headwind.","sector":"Staffing, BPO \u0026 Professional Services","time_horizon":"1_to_4_weeks"}

Who it hits first

  • Health-IT / digital-health software vendors and system integrators that build the registries, citizen apps and interoperability layers (TATAELXSI, NETWEB, PROTEAN) see anticipatory demand
  • National drug registry adds batch-level traceability/serialization compliance obligations for pharma makers (e.g. THEMISMED)

Who may gain

  • TATAELXSI - healthcare digital-engineering vertical
  • NETWEB - HPC / data-centre / AI-server backbone for registries and analytics
  • PROTEAN - builder/operator of govt digital public infrastructure (closest fit to the health stack)

Along the supply chain

Downstream

Downstream, hospitals and diagnostics chains (HCG) must integrate interoperable records (near-term integration cost, gradual efficiency benefit) and pharma manufacturers/distributors (THEMISMED) must adapt dispensing, serialization and recall workflows to the national drug registry.

Upstream

Registry/app build-out pulls demand to upstream compute and connectivity suppliers - HPC servers and data-centre hardware (NETWEB) and last-mile/rural connectivity (NELCO) - plus cybersecurity and cloud-hosting vendors that secure sensitive health data.

Where demand moves

Business

Govt digital-health platform build-out creates new orders for health-IT software vendors, system integrators and digital-public-infrastructure operators (TATAELXSI, PROTEAN), and for the compute/data-centre backbone (NETWEB); pharma makers face new drug-registry compliance/serialization spend that flows to packaging, track-and-trace and pharma-IT vendors.

Capital

Anticipatory, theme-driven buying rotates toward listed health-IT and digital-public-infrastructure proxies (TATAELXSI, NETWEB, PROTEAN) on the launch news; given rich valuations and no awarded tenders, flows are likely shallow and selective rather than a broad sector re-rating.

How it spreads across sectors

Healthcare

Hospitals and diagnostics adopt interoperable records; near-term integration cost, gradual efficiency benefit (mixed)

Information Technology

Demand for govt health-IT build-out, system integration and digital-public-infrastructure platforms (positive, anticipatory)

Pharma

Drug registry drives serialization/traceability compliance spend; near-term cost, medium-term formalization (mixed)

codex additions

When it plays out

Immediate

June 29 launch generates theme-driven, anticipatory interest in listed health-IT / digital-public-infrastructure proxies; little fundamental change until tenders/contracts are awarded

Medium term

If the digital-health stack scales (registries, interoperability, AI workloads), structural demand builds for health-IT, data-centre/compute, cybersecurity and track-and-trace vendors; formalization may modestly favour organized pharma

Short term

Watch for actual procurement, tenders and system-integrator awards (incl. govt cloud/NIC routing) that would convert the theme into revenue; pharma begins assessing drug-registry compliance load

Other sectors it reaches

  • {"causal_chain":"Interoperable health records and registries can reduce claims friction, improve underwriting data, enable faster pre-authorisation and fraud checks; insurers may need integration spend but benefit from cleaner digital rails over time.","direction":"mixed","example_tickers":["STARHEALTH","ICICIGI","NIACL"],"magnitude":"medium","notes":"Near-term compliance/integration cost; medium-term operating efficiency and product-design upside.","sector":"Health Insurance / Insurtech","time_horizon":"1_to_6_months"}
  • {"causal_chain":"Citizen apps, telemedicine, provider registries and rural digital-health access increase dependence on reliable mobile data, broadband, enterprise connectivity and last-mile uptime.","direction":"positive","example_tickers":["BHARTIARTL","TATACOMM","INDUSTOWER"],"magnitude":"medium","notes":"Most visible where public-health workflows extend into rural clinics, pharmacies and district hospitals.","sector":"Telecom Connectivity / Broadband Infrastructure","time_horizon":"1_to_4_weeks"}
  • {"causal_chain":"National registries, health IDs, consent systems, analytics and AI workloads require secure hosting, storage, uptime, cooling and backup-power infrastructure.","direction":"positive","example_tickers":["ANANTRAJ","BLUESTARCO","CUMMINSIND"],"magnitude":"medium","notes":"Indirect capex beneficiary; demand may route through cloud/data-centre operators and government system integrators.","sector":"Data Centres, Power Backup and Cooling","time_horizon":"1_to_6_months"}
  • {"causal_chain":"Large-scale health records and drug registries raise privacy, identity, consent-management and cyber-risk requirements, creating demand for endpoint security, audits, encryption and incident-response services.","direction":"positive","example_tickers":["QUICKHEAL","TAC","63MOONS"],"magnitude":"medium","notes":"Health data sensitivity makes security spend politically and operationally hard to defer.","sector":"Cybersecurity / Digital Trust","time_horizon":"immediate"}
  • {"causal_chain":"A national drug registry can push manufacturers and distributors toward better batch-level traceability, QR/barcode labelling, anti-counterfeit packaging and serialization workflows.","direction":"positive","example_tickers":["UFLEX","EPL","TCPLPACK"],"magnitude":"medium","notes":"Upside depends on how mandatory and granular registry compliance becomes.","sector":"Packaging, Labelling and Track-and-Trace","time_horizon":"1_to_6_months"}
  • {"causal_chain":"Drug registry integration can change inventory verification, recall management, substitution checks and dispensing workflows for wholesalers, chains and online pharmacies.","direction":"mixed","example_tickers":["MEDPLUS","APOLLOHOSP","ENTERO"],"magnitude":"medium","notes":"Compliance burden initially negative; larger organised players may gain share from better ability to integrate.","sector":"Pharma Distribution / Retail Pharmacy","time_horizon":"1_to_4_weeks"}
  • {"causal_chain":"Better drug traceability and digital inventory records can increase formal logistics requirements, especially for temperature-sensitive medicines, vaccines and recall-ready supply chains.","direction":"positive","example_tickers":["TCIEXP","MAHLOG","VRLLOG"],"magnitude":"small","notes":"More relevant if registry rules extend into distribution-chain reporting and batch-level movement tracking.","sector":"Logistics and Cold Chain","time_horizon":"1_to_6_months"}
  • {"causal_chain":"Provider-focused digital solutions and interoperable records increase demand for connected devices, hospital IT-linked equipment, patient monitoring systems and digitised clinical workflows.","direction":"positive","example_tickers":["POLYMED","BPL","KRSNAA"],"magnitude":"small","notes":"Indirect beneficiary through hospitals upgrading devices and workflow capture around digital records.","sector":"Medical Devices and Hospital Equipment","time_horizon":"1_to_6_months"}
  • {"causal_chain":"Citizen health apps, digital claims, teleconsultations, pharmacy purchases and public-health benefit flows can increase embedded payment, reconciliation and identity-linked transaction use cases.","direction":"positive","example_tickers":["PAYTM","NSDL","CAMS"],"magnitude":"small","notes":"Likely second-order; strongest if government health apps include payments, reimbursements or benefit-transfer layers.","sector":"Digital Payments / Fintech Rails","time_horizon":"1_to_6_months"}

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

28 Aug 2026unspecified₹10
29 Aug 2025unspecified₹10

Splits, bonuses & buybacks

  • daily-prices repair: 3 rows from NSE's archive (replace 1, delete 1, insert 1), 2025-03-18..2026-02-01 (docs/flat_day_repair.md)1× · 18 Mar 2025

Bulk & block deals

DateWhoBought / soldSharesPrice
28 Sep 2026HRTI PRIVATE LIMITEDSELL2,43,192₹698.72
28 Sep 2026HRTI PRIVATE LIMITEDBUY2,42,723₹696.70
25 Sep 2026HRTI PRIVATE LIMITEDBUY2,19,727₹671.97
25 Sep 2026HRTI PRIVATE LIMITEDSELL2,19,167₹669.04
22 Sep 2026MICROCURVES TRADING PRIVATE LIMITEDBUY7,72,945₹630.66
22 Sep 2026MICROCURVES TRADING PRIVATE LIMITEDSELL7,72,889₹631.00
22 Sep 2026ALPHAGREP SECURITIES PRIVATE LIMITEDBUY7,43,508₹627.86
22 Sep 2026ALPHAGREP SECURITIES PRIVATE LIMITEDSELL7,43,508₹627.47
22 Sep 2026QE SECURITIES LLPSELL7,22,847₹626.16
22 Sep 2026QE SECURITIES LLPBUY7,20,296₹626.61

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.